Ghent, Belgium

Nele Juchtmans

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: University of Ghent, Vib Vzw. Active years: 2019.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nele Juchtmans: Innovator in Bone Disease Treatment

Introduction

Nele Juchtmans is a notable inventor based in Ghent, Belgium. He has made significant contributions to the field of medical science, particularly in the treatment of bone diseases. His innovative approach has led to the development of a unique method that addresses critical issues related to bone health.

Latest Patents

Juchtmans holds a patent for a "Method of treating bone disease." This patent encompasses compositions and methods that utilize a sialoadhesin binding moiety for treating metabolic and genetic bone diseases. His work specifically targets bone disorders characterized by hyper-resorption of bone and enhanced activation of osteoclasts. This innovative treatment has the potential to improve the quality of life for individuals suffering from such conditions.

Career Highlights

Throughout his career, Nele Juchtmans has been associated with prestigious institutions, including the University of Ghent and VIB VZW. His work in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his research and development efforts.

Collaborations

Some of his notable collaborators include Dirk Elewaut and Els Louagie. Their combined expertise has contributed to the advancement of research in bone disease treatment.

Conclusion

Nele Juchtmans is a pioneering inventor whose work in treating bone diseases has the potential to make a significant impact in the medical field. His innovative methods and collaborations with esteemed colleagues highlight his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…